Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13346-020-00769-6 http://scihub22266oqcxt.onion/10.1007/s13346-020-00769-6 32385828!7209970!32385828     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Deliv+Transl+Res 2020 ; 10 (3): 567-570 Nephropedia Template TP {{tp|p=32385828|t=2020. From micro to nano: evolution and impact of drug delivery in treating disease |pdf=|usr=}}{{32385828}} gab.com Text From micro to nano: evolution and impact of drug delivery in treating disease JO: Drug Deliv Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=32385828 #FOAvip Over the past 50 years, drug delivery breakthroughs have enabled the approval of several important medicines. Often, this path starts with innovation from academic collaborations amongst biologists, chemists, and engineers, followed by the formation of a start-up company driving clinical translation and approval. An early wave featured injectable (i.e., intramuscular, subcutaneous) biodegradable polymeric microspheres to control drug release profiles for peptides and small molecules (e.g., Lupron Depot(R), Risperdal Consta(R)). With these early successes for microspheres, research shifted to exploring systemic delivery by intravenous injection, which required smaller particle sizes and modified surface properties (e.g., PEGylation) to enable long circulation times. These new innovations resulted in the nanoparticle medicines Doxil(R) and Abraxane(R), designed to improve the therapeutic index of cytotoxic cancer agents by decreasing systemic exposure and delivering more drug to tumors. Very recently, the first siRNA lipid nanoparticle medicine, Patisiran (Onpattro(R)), was approved for treating hereditary transthyretin-mediated amyloidosis. In this inspirational note, we will highlight the technological evolution of drug delivery from micro- to nano-, citing some of the approved medicines demonstrating the significant impact of the drug delivery field in treating many diseases. Twit Text FOAVip From micro to nano: evolution and impact of drug delivery in treating disease ????Drug Deliv Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=32385828 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32385828 #FOAvip English Wikipedia <ref>{{Cite pmid|32385828}}</ref> From micro to nano: evolution and impact of drug delivery in treating disease #MMPMID32385828 Hrkach J; Langer R Drug Deliv Transl Res 2020[Jun]; 10 (3): 567-570 PMID32385828show ga Over the past 50 years, drug delivery breakthroughs have enabled the approval of several important medicines. Often, this path starts with innovation from academic collaborations amongst biologists, chemists, and engineers, followed by the formation of a start-up company driving clinical translation and approval. An early wave featured injectable (i.e., intramuscular, subcutaneous) biodegradable polymeric microspheres to control drug release profiles for peptides and small molecules (e.g., Lupron Depot(R), Risperdal Consta(R)). With these early successes for microspheres, research shifted to exploring systemic delivery by intravenous injection, which required smaller particle sizes and modified surface properties (e.g., PEGylation) to enable long circulation times. These new innovations resulted in the nanoparticle medicines Doxil(R) and Abraxane(R), designed to improve the therapeutic index of cytotoxic cancer agents by decreasing systemic exposure and delivering more drug to tumors. Very recently, the first siRNA lipid nanoparticle medicine, Patisiran (Onpattro(R)), was approved for treating hereditary transthyretin-mediated amyloidosis. In this inspirational note, we will highlight the technological evolution of drug delivery from micro- to nano-, citing some of the approved medicines demonstrating the significant impact of the drug delivery field in treating many diseases. |Clinical Trials as Topic[MESH] |Drug Approval[MESH] |Drug Delivery Systems/*methods/*trends[MESH] |Humans[MESH] |Microtechnology[MESH] |Nanoparticles[MESH] |Peptides[MESH]From micro to nano: evolution and impact of drug delivery in treating (epmc).pdf DeepDyve Pubget Overpricing